On the cusp of FDA approval for its NASH drug, Intercept’s CEO talks payers, pruritis, and price

It’s been a long and bumpy road, but Intercept’s NASH drug, called obeticholic acid, is finally on the cusp of a FDA approval. 

Click to view original post